Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent.

OBJECTIVES To develop a population pharmacokinetic model for romidepsin given as an HIV latency reversing agent (LRA) and to explore the relationship between romidepsin exposure and its in vivo effects on viral gene expression and antiviral immunity. METHODS A population pharmacokinetic analysis was performed in 15 HIV-1-infected patients who received three weekly infusions of romidepsin (5 mg/m2) within the BCN02 clinical trial. A full pharmacokinetic profile was obtained for each participant at the first dose, and additional samples thereafter. A population pharmacokinetic model was developed. Bayesian estimates of the individual pharmacokinetic parameters of romidepsin were used to simulate individual time-concentration curves on each occasion. The relationship between romidepsin AUC0-∞ and its in vivo effects was assessed. RESULTS Romidepsin pharmacokinetics were best described by a three-compartment model with linear kinetics. Body weight influenced romidepsin disposition. A significant relationship was observed between romidepsin AUC0-∞ and increases in expression of exhaustion markers by CD4+ and CD8+ T cells and apoptosis markers in CD4+, but not with histone acetylation levels or HIV-1 cell-associated RNA in CD4+ T cells. For each increase of 100 ng·h/mL in romidepsin AUC0-∞, CD4+ counts decreased by a mean (95% CI) of 74 (42-94) cells/mm3 after dosing. CONCLUSIONS A population model describing the pharmacokinetics of romidepsin as an HIV LRA was developed. Higher exposure to romidepsin resulted in higher expression of apoptosis markers and declines in CD4+ count but did not increase viral reactivation levels. These observations have important implications for the optimization of effective kick-and-kill strategies for an HIV-1 cure.

[1]  C. Brander,et al.  Novel Approaches Towards a Functional Cure of HIV/AIDS , 2020, Drugs.

[2]  B. Clotet,et al.  HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02) , 2020, Frontiers in Immunology.

[3]  B. Clotet,et al.  In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial , 2020, Frontiers in Immunology.

[4]  S. Lewin,et al.  Barriers and strategies to achieve a cure for HIV. , 2018, The lancet. HIV.

[5]  R. Siliciano,et al.  Targeting the Latent Reservoir for HIV‐1 , 2018, Immunity.

[6]  R. Paredes,et al.  Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B , 2017, PloS one.

[7]  E. Hernández-Vargas Modeling Kick-Kill Strategies toward HIV Cure , 2017, Front. Immunol..

[8]  M. Tolstrup,et al.  Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial. , 2016, The lancet. HIV.

[9]  G. Pantaleo,et al.  The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo , 2015, PLoS pathogens.

[10]  D. Hazuda,et al.  Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy , 2014, PLoS pathogens.

[11]  D. Irvine,et al.  Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes , 2014, PLoS pathogens.

[12]  C. Spina,et al.  Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing , 2014, PLoS pathogens.

[13]  D. Margolis,et al.  Emerging strategies to deplete the HIV reservoir , 2014, Current opinion in infectious diseases.

[14]  T. Fojo,et al.  Phase I Trial of a New Schedule of Romidepsin in Patients with Advanced Cancers , 2013, Clinical Cancer Research.

[15]  E. Verdin,et al.  Reactivation of latent HIV by histone deacetylase inhibitors. , 2013, Trends in microbiology.

[16]  R. Siliciano,et al.  Redefining the viral reservoirs that prevent HIV-1 eradication. , 2012, Immunity.

[17]  J. Eron,et al.  Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy , 2012, Nature.

[18]  R. Siliciano,et al.  Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. , 2012, Immunity.

[19]  P. Atadja Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. , 2009, Cancer letters.

[20]  Arsène Burny,et al.  Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection , 2009, PloS one.

[21]  S. Bates,et al.  Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma , 2009, Clinical Cancer Research.

[22]  Ross J. Harris,et al.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2008, The Lancet.

[23]  J. Coffin,et al.  Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells , 2008, AIDS.

[24]  W. Figg,et al.  Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection. , 2008, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[25]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[26]  P. Houghton,et al.  Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Grever,et al.  A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. , 2004, Blood.

[28]  B. Clotet,et al.  Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects. , 2004, AIDS research and human retroviruses.

[29]  S. Bates,et al.  Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[31]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[32]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[33]  D. Richman,et al.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. , 1997, Science.